Latest Research And Development News

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.

Sparc Technologies has secured a fourth trial agreement with BHP Mitsubishi Alliance to test its graphene-enhanced ecosparc® coating in harsh mining conditions, aiming to validate its anti-corrosive performance against market leaders.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.

Gold Hydrogen Limited has secured a $6.45 million R&D tax refund, strengthening its financial position ahead of an ambitious 2025 drilling campaign. The company also announced key leadership changes, including the appointment of a seasoned Chief Geologist.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Entyr Limited has received a $3.79 million R&D tax incentive payment for its innovative thermal desorption project targeting rubber waste, reinforcing its position in sustainable tyre recycling technology.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.

WA Kaolin Ltd has marked a pivotal operational milestone in Q4 2024 with the successful commissioning of its classifier project, boosting production and product quality. The company is now poised for growth with increasing sales and a planned equity capital raising.